Shell PLC vs Twist Bioscience Corp — how do they compare? Shell PLC trades at $90.14 (market cap $250.44B), while Twist Bioscience Corp trades at $123.63 (market cap $7.72B). The key difference: Shell PLC is far larger — about 32.4× Twist Bioscience Corp's market cap, and Shell PLC pays a 3.45% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| SHEL | TWST | |
|---|---|---|
Market Cap | $250.44B | $7.72B |
Sector | Energy | Health |
52-Week High | $94.15 | $124.88 |
52-Week Low | $70.31 | $24.16 |
Enterprise Value | $292.14B | $7.65B |
Dividend Yield | 3.45% | — |
Signals from Pluang's Aura AI — not financial advice
Shell (SHEL) trades at $89.95, up 1.64% today, with a bullish technical signal from moving averages and strong Q2 2026 earnings beats. The stock shows attractive valuation with a P/E of 10.01 and P/S of 0.88, supported by robust cash flow and a 14.35% ROE. Recent news highlights oil price gains boosting energy stocks and Shell's strategic divestments in renewables.
Outlook is positive with a $103.60 consensus price target and 69% buy ratings, though risks include commodity volatility and regulatory pressures. Earnings growth and debt reduction provide upside, while geopolitical tensions and energy transition uncertainties remain key watchpoints for investors.
TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.
The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.
Trailing returns across standard periods
Latest headlines on both assets
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →